By 2060, the CDC projects that the Latino population will experience the largest increase in Alzheimer’s disease and related dementia (ADRD) cases of all US ethnic/racial groups. The main explanation for high Latino ADRD is attributed largely to early and excess cardiovascular disease (CVD) morbidity contributing to disparately high ADRD. CVD risk factors emerge early in midlife among Latinos, thereby increasing exposures to exquisitely sensitive and highly vascularized brain tissue. Yet, to-date there has not been any study of Latinos with sufficiently deep CVD phenotyping and genotyping to adequately address this significant public health question. This scientific knowledge gap is a significant impediment to the field and public health given rapid Latino population growth projections, particularly for older adults. The Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer’s Disease (SOL-INCA-AD) will augment the ongoing large, representative and unique cohort with 10-years of advanced biomarkers of Alzheimer's disease to understand cognitive aging and impairment amongst diverse Latinos. Together with 10-years of cognitive measures, MRI, deep CVD phenotyping, genomics and rich sociocultural data, SOL-INCA-AD is a high priority study that will fill major scientific knowledge gaps that form barriers to progress for Latino ADRD research.

The Competitive Renewal of the Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer’s Disease (SOL-INCA-AD) leverages the ongoing Hispanic Community Health Study/Study of Latinos (HCHS/SOL; NHLBI; n=16,415) and its 10-years of rich cognitive, sociocultural, cardiovascular, and genetic and MRI data to understand Latino Alzheimer’s disease and related dementias. The SOL-INCA-AD project will augment the ongoing cohort with 10-years of advanced biomarkers of Alzheimer's disease and related dementias to understand the pathobiology of cognitive aging and impairment amongst diverse Latinos. The SOL-INCA-AD goal is to identify critical periods in adulthood when vascular disease and AD biomarkers affect cognitive decline and impairment to more precisely guide ADRD public health prevention and therapeutic interventions for diverse Latinos, which will apply to other diverse populations.